MOTS-C (mitochondrial open reading frame of the 12S rRNA-c) is one of the most studied mitochondrial-derived peptides in modern metabolic research. Since its discovery in 2015, it has become a focal point for laboratories investigating how mitochondria communicate with the rest of the cell — and how that signaling influences metabolism, aging, and physical performance in research models.
This guide summarizes what MOTS-C is, how it behaves in published studies, and how research laboratories handle it — strictly from a scientific, research-use perspective.
MOTS-C is a 16-amino-acid peptide encoded by a short open reading frame (sORF) located within the mitochondrial 12S rRNA region of mitochondrial DNA (mtDNA). It was first described in 2015 by Lee et al. in the journal Cell Metabolism, emerging from the laboratory of Pinchas Cohen at the University of Southern California.
The discovery was significant for a simple reason: the mitochondrial genome was long thought to encode only 13 proteins involved in energy production. The identification of MOTS-C — following the earlier discovery of humanin — showed that mitochondria also produce small signaling peptides, collectively called mitochondrial-derived peptides (MDPs), that can act well beyond the organelle itself.
In research literature, MOTS-C is often described as a “mitokine”: a mitochondria-originated signaling molecule that can be detected in tissues such as skeletal muscle and in circulation. Its primary target organ in animal studies appears to be skeletal muscle, though it has been detected in multiple tissues.
The mechanism of action proposed for MOTS-C centers on cellular energy sensing. According to the foundational 2015 study, MOTS-C’s cellular actions inhibit the folate cycle and its tethered de novo purine biosynthesis pathway. This inhibition leads to the accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), which in turn activates AMPK (AMP-activated protein kinase) — a master regulator of cellular energy homeostasis.
In practical terms, researchers describe this as the folate–purine–AMPK pathway: MOTS-C → folate cycle inhibition → AICAR buildup → AMPK activation → downstream metabolic effects.
Additional research has revealed a second, striking behavior. Under conditions of metabolic stress, MOTS-C can translocate from the cytoplasm into the nucleus, where it interacts with stress-responsive transcription factors such as NRF2 and associated gene networks. This suggests MOTS-C participates in direct mitochondria-to-nucleus communication, helping cells mount an adaptive response to metabolic challenge.
It is important to emphasize that these mechanisms have been characterized in cell models and animal studies. The precise signaling picture in humans remains an active area of investigation.
The landmark Lee et al. (2015) study reported that MOTS-C treatment in mice prevented both age-dependent and high-fat-diet-induced insulin resistance, as well as diet-induced obesity. The authors concluded that mitochondria may actively regulate metabolic homeostasis at the cellular and organismal level through genome-encoded peptides — a finding that helped launch the broader MDP research field.
A 2021 study published in Nature Communications (Reynolds et al.) investigated MOTS-C in the context of exercise. The researchers found that endogenous MOTS-C levels in human skeletal muscle and plasma increased significantly after a bout of stationary cycling, suggesting that exercise induces the expression of this mitochondrial-encoded peptide. In mice, MOTS-C treatment improved physical performance across young, middle-aged, and old animals and regulated skeletal muscle gene expression. These findings led some researchers to describe MOTS-C as an exercise-associated mitochondrial regulator — a characterization grounded in observed data, not a claim of equivalence to exercise.
A 2016 study in Biochemical and Biophysical Research Communications examined MOTS-C in a mouse model of ovariectomy-induced bone loss. The researchers reported that MOTS-C treatment alleviated bone loss as measured by micro-CT, an effect linked to AMPK-dependent inhibition of osteoclast differentiation. As with other findings, this work was conducted in animals and warrants cautious interpretation.
More recent work (2024) explored MOTS-C in a streptozotocin-induced diabetic neuropathy model in mice. The study reported improvements in pain-related measures alongside AMPK/PGC-1α pathway activation, restored mitochondrial biogenesis markers, and reduced microglial activation. The authors framed these results as early pharmacological evidence rather than established therapeutic conclusions.
Human research on MOTS-C remains largely observational. Studies have associated lower circulating MOTS-C levels with insulin resistance and impaired coronary endothelial function. A genetic polymorphism (K14Q) that alters the MOTS-C amino acid sequence has been proposed as a contributor to type 2 diabetes risk in sedentary men. A 2025 study found serum MOTS-C levels inversely correlated with obstructive sleep apnea severity. These are associations, not demonstrations of cause and effect, and they underscore how much remains to be learned.
Laboratory studies have also examined MOTS-C in cell models, including work on ovarian cancer cell lines where MOTS-C was reported to suppress proliferation through interactions with the ubiquitin–proteasome system. This line of inquiry is at an early, preclinical stage.
The consistent thread: across these studies, AMPK activation appears again and again as the central node of MOTS-C’s observed effects. For research laboratories, that makes MOTS-C a useful tool compound for probing mitochondrial signaling and energy-sensing pathways.
For laboratories working with synthetic MOTS-C, standard peptide-handling practices apply. These are general laboratory procedures, not instructions for any other use.
Lyophilized storage. Lyophilized (freeze-dried) MOTS-C is typically stored at −20 °C or below, protected from light and moisture. Under these conditions, lyophilized peptides generally remain stable for extended periods; always follow the storage guidance supplied with the specific lot.
Reconstitution. In the laboratory, lyophilized peptides are reconstituted using sterile water or bacteriostatic water according to the lab’s own validated protocol, with the diluent and final concentration chosen based on the experimental design. Solutions should be prepared with sterile technique.
After reconstitution. Reconstituted peptide solutions are generally stored refrigerated (2–8 °C) for short-term use or aliquoted and frozen for longer storage. Repeated freeze–thaw cycles are best avoided, as they can degrade peptide integrity — aliquoting into single-use volumes is standard practice.
Quality verification. Because experimental results depend on material quality, many labs confirm peptide identity and purity before use. NUPEPS provides a certificate of analysis (COA) for its MOTS-C products, and every batch is evaluated by an independent ISO/IEC 17025:2017-accredited laboratory for purity, quantity, and sterility.
MOTS-C stands for “mitochondrial open reading frame of the 12S rRNA-c.” The name reflects its origin: it is encoded by a short open reading frame within the mitochondrial 12S ribosomal RNA region.
MOTS-C is 16 amino acids long, making it one of the smallest known mitochondrial-derived peptides.
Both are mitochondrial-derived peptides, but they come from different regions of the mitochondrial genome: humanin is encoded within the 16S rRNA region, while MOTS-C comes from the 12S rRNA region. They also appear to act through different primary pathways in published research.
Direct interventional studies in humans are limited. Most human data comes from observational research — for example, studies measuring circulating MOTS-C levels in relation to exercise, insulin resistance, or sleep apnea — and from the well-documented 2021 finding that exercise acutely raises endogenous MOTS-C in muscle and plasma. The bulk of mechanistic evidence comes from cell and animal models.
Because it sits at the intersection of several major research areas: mitochondrial signaling, AMPK-mediated energy regulation, metabolic homeostasis, aging biology, and exercise physiology. As a defined, synthesizable 16-amino-acid peptide, it gives laboratories a precise tool for probing these pathways.
A decade after its discovery, MOTS-C remains one of the most intriguing molecules in mitochondrial biology — a tiny peptide encoded in the mitochondrial genome that appears to coordinate metabolic responses through the AMPK pathway and direct nuclear signaling. While the science is still evolving, particularly in humans, the published record gives research laboratories a solid foundation for further investigation.
For laboratories planning MOTS-C research, material quality is the starting point. NUPEPS offers MOTS-C 20MG research peptide, supplied lyophilized with a batch-specific certificate of analysis verifying purity of 99% or greater. Browse the full range of research peptides to support your next study.
Research Use Only disclaimer: All NUPEPS products, including MOTS-C, are sold strictly for laboratory and in vitro research use only. They are not intended for human or veterinary use, nor for the diagnosis, treatment, cure, or prevention of any disease. This article is for informational purposes only and summarizes published scientific literature; it does not constitute medical or scientific advice.
Peptides are short chains of amino acids used in scientific research to study biological pathways, mimic protein regions, and support assay and method development.
NUPEPS Peptides™ offers guaranteed national delivery, shipping times may vary due to carrier or transportation conditions. Reshipment is provided one time at no cost if non-delivery is confirmed.
Secure Checkout
Fast Shipping
Easy Returns
